-- Expected to establish a leading global provider of full-spectrum, preclinical and clinical biotherapeutics and biomarker analysis solutions --
-- Expected to enhance scale, broaden customer base and create significant cross-selling opportunities --
This collaboration will provide Synexa with further international expansion of its clinical biomarker and bioanalytical offering. Under this commercial collaboration, Synexa will support
“The evolving complexity of novel biotherapeutics, such as cell and gene therapies, requires laboratories with real expertise to develop and validate methods and to perform analysis in the preclinical and clinical fields to satisfy the scrutiny of international regulatory authorities throughout the entirety of the drug development process,” said
“We are very excited to combine forces with
Benefits of the Collaboration
The expected benefits of the collaboration include:
- Simplifying the outsourcing of preclinical and clinical regulated biotherapeutics and biomarker services.
- Building preferred provider partnerships with fast-growing biopharmaceutical companies, focusing on a pipeline/follow-the-molecule approach.
- Combining deep scientific expertise across the DNA-RNA-Protein-Cell-Tissue continuum.
- Delivering potential cost and revenue synergies through SG&A expense savings and cross-selling existing clients across a broader platform of services.
About
About Synexa
Synexa Life Sciences is a global leader the application of biomarker and bioanalytical science to help biopharma clients meet their clinical development targets. Founded in 2003 as an early pioneer in the biomarker field, Synexa specializes in the development, validation and delivery of a wide range of complex and custom-designed assays, based on deep expertise in immunology and the impact of the immune system on human health and candidate drug performance. Headquartered at the
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the
Company Contact | Investor Relations | |
(765) 497-8381 | (212) 836-9614 | |
btaylor@inotivco.com | kahl@equityny.com | |
(212) 836-9608 | ||
dsullivan@equityny.com |
![](https://ml.globenewswire.com/media/ZWRlMDg1YTgtNDU1OS00NzkyLTkyMDUtNjJiNDJkNmU0OTA2LTEwMjEyNDA=/tiny/Inotiv-Inc-.png)
2022 GlobeNewswire, Inc., source